PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 27, 2025Acta cardiologica. Supplementum2 citationsOpen Access

The protective role of dapagliflozin on the noreflow phenomenon in type 2 diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention

View Full Paper
CKCemal KöseoğluAÇAli ÇonerCÖCan Ramazan Öncel

Structured PICO

Does dapagliflozin affect the no-reflow phenomenon in patients with type 2 diabetes mellitus and acute myocardial infarction undergoing percutaneous coronary intervention?

P
Population
Patients with type 2 diabetes mellitus (T2DM) and acute myocardial infarction undergoing percutaneous coronary intervention
I
Intervention
Dapagliflozin
O
Outcome
No-reflow phenomenon

This letter to the editor discusses a study on the effect of dapagliflozin on the no-reflow phenomenon in patients with T2DM and acute myocardial infarction undergoing PCI.

Abstract

To the Editor,We have read the article by Quisi et al. 1 which explored the effect of dapagliflozin on the noreflow phenomenon in patients with type 2 diabetes mellitus (T2DM) and acute myocardia...

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Köseoğlu et al. (2025) studied this question.

synapsesocial.com/papers/6a7d167ec66da78fab8b1f4ahttps://doi.org/10.1080/00015385.2025.2511523
Ask AI
Helpful
Bookmark
Share
View Full Paper